Li Ninglei, Liu Xiaolong, Han Luzhe, Zhou Rui, Yan Jian, Zhao Guoxiang, Liu Lixin
Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Oncol Lett. 2019 Jun;17(6):4871-4876. doi: 10.3892/ol.2019.10173. Epub 2019 Mar 20.
The expression level of microRNA (miRNA)-146b in patients with thyroid carcinoma (TC) in combination with Hashimoto's thyroditis (HT) was evaluated to analyze the clinical significance. Eighty-seven patients who underwent thyroid surgery in The Third Affiliated Hospital of Southern Medical University from March 2010 to February 2013 were enrolled. Of the patients, 37 were diagnosed with TC (group A), and 50 were diagnosed with TC in combination with HT (group B). Forty patients were diagnosed with HT (group C). The expression levels of miRNA-146b-5p in cancer tissue and paracancerous tissue of patients in the two groups were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Correlation between the miRNA-146b-5p levels and the clinicopathological characteristics of patients with combined TC and HT were evaluated. According to the expression of miRNA-146b-5p, patients in group B were separated into the high and low expression groups to observe the five-year cancer recurrence rate. There was no significant difference in miRNA-146b-5p expression between the papillary carcinoma group, the follicular carcinoma group and the medullary carcinoma group (P>0.05). The miRNA-146b-5p expression in the lesion tissue of group B was significantly higher than that of groups A and C, while the miRNA-146b-5p expression in the lesion tissue of group A was significantly higher than that of group C (P<0.05), and the lesion tissue of the three groups was higher than that of the corresponding parastatal tissue (P<0.05). The miRNA-146b-5p expression level was associated with tumor size, lymph node metastasis and TNM stage (P<0.05), while not associated with sex, age, lesion multiplicity, smoking history, diabetes history and pathological type in group B (P>0.05). The non-recurrence rate of group B high expression subgroup was lower than that of group B low expression subgroup (P=0.045). High expression of miRNA-146b-5p was found in the cancer tissues of patients with combined TC and HT. The expression level of miRNA-146b-5p was associated with tumor size, lymph node metastasis and TNM stage. It is a potential prognostic indicator for patients with combined TC and HT.
评估甲状腺癌(TC)合并桥本甲状腺炎(HT)患者中微小RNA(miRNA)-146b的表达水平,以分析其临床意义。纳入2010年3月至2013年2月在南方医科大学第三附属医院接受甲状腺手术的87例患者。其中,37例诊断为TC(A组),50例诊断为TC合并HT(B组)。40例诊断为HT(C组)。采用逆转录-定量聚合酶链反应(RT-qPCR)检测两组患者癌组织及癌旁组织中miRNA-146b-5p的表达水平。评估miRNA-146b-5p水平与TC合并HT患者临床病理特征的相关性。根据miRNA-146b-5p的表达情况,将B组患者分为高表达组和低表达组,观察五年癌症复发率。乳头状癌组、滤泡状癌组和髓样癌组之间miRNA-146b-5p表达无显著差异(P>0.05)。B组病变组织中miRNA-146b-5p表达明显高于A组和C组,而A组病变组织中miRNA-146b-5p表达明显高于C组(P<0.05),三组病变组织均高于相应癌旁组织(P<0.05)。miRNA-146b-5p表达水平与肿瘤大小、淋巴结转移及TNM分期相关(P<0.05),而与B组患者的性别、年龄、病变数量、吸烟史、糖尿病史及病理类型无关(P>0.05)。B组高表达亚组的无复发率低于B组低表达亚组(P=0.045)。在TC合并HT患者的癌组织中发现miRNA-146b-5p高表达。miRNA-146b-5p表达水平与肿瘤大小、淋巴结转移及TNM分期相关。它是TC合并HT患者的潜在预后指标。